-
Oct 2024
Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapy.
J AutoimmunTewari R, Yang SJ, McClain ED, Hu A, Mortensen E, DeSchmidt A, Chen J, Kancharla A, Singh AK, James EA, Burman BE, Siddique A, Rawlings DJ, Patel C, Cerosaletti K, Buckner JH -
Feb 2024
GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.
JCI InsightUenishi GI, Repic M, Yam JY, Landuyt A, Saikumar-Lakshmi P, Guo T, Zarin P, Sassone-Corsi M, Chicoine A, Kellogg H, Hunt M, Drow T, Tewari R, Cook PJ, Yang SJ, Cerosaletti K, Schweinoch D, Guiastrennec B, James E, Patel C, Chen TF, Buckner JH, Rawlings DJ, Wickham TJ, Mueller KT -
Jul 2023
Dual-locus, dual-HDR editing permits efficient generation of antigen-specific, regulatory T cells with robust suppressive activity.
Mol TherHunt MS, Yang SJ, Mortensen E, Boukhris A, Buckner J, Cook PJ, Rawlings DJ -
Oct 2022
Pancreatic islet-specific engineered Tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models.
Sci Transl MedYang SJ, Singh AK, Drow T, Tappen T, Honaker Y, Barahmand-Pour-Whitman F, Linsley PS, Cerosaletti K, Mauk K, Xiang Y, Smith J, Mortensen E, Cook PJ, Sommer K, Khan I, Liggitt D, Rawlings DJ, Buckner JH -
Jun 2020
Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function.
Sci Transl MedHonaker Y, Hubbard N, Xiang Y, Fisher L, Hagin D, Sommer K, Song Y, Yang SJ, Lopez C, Tappen T, Dam EM, Khan I, Hale M, Buckner JH, Scharenberg AM, Torgerson TR, Rawlings DJ
